Vertex Pharmaceuticals, the biotech known for its cystic fibrosis franchise and newer pain therapy Journavx, is facing fresh scrutiny over its $10 billion…
Vertex Pharmaceuticals, the biotech known for its cystic fibrosis franchise and newer pain therapy Journavx, is facing fresh scrutiny over its $10 billion agreement to buy Crinetics Pharmaceuticals. Newly released deal documents show Vertex sole bidder status in the process, a detail now fueling debate over whether the company paid too much for its biggest acquisition ever.
Key Takeaways
- Vertex agreed to buy Crinetics for $85 per share, a 102% premium to the prior closing price.
- Filings show Vertex was the only company that stayed in the bidding process through to a final agreement.
- Crinetics markets one drug for a rare hormonal disorder and has a late-stage treatment for congenital adrenal hyperplasia in testing.
- Vertex projects the two therapies could eventually bring in more than $5 billion annually at peak sales.
- Analysts are split on whether the price reflects overconfidence or simply reflects Vertex's confidence in the assets.
How the Vertex Sole Bidder Story Unfolded
The negotiation traces back to the J.P. Morgan Healthcare Conference in January, where Crinetics representatives met with Vertex's business development team in what filings describe as routine industry contact. Two months later, on March 14, Vertex approached Crinetics chief executive R. Scott Struthers directly. By March 24, Vertex had floated $78 a share, a 125% premium at the time.
Crinetics brought in Leerink Partners and J.P. Morgan as advisors and spent roughly ten days weighing the offer before its board rejected it on April 5, betting Vertex would return with more. That bet paid off, sort of: Vertex came back on April 19 with $83 a share, still short of what the board wanted. Directors turned that down too and quietly built a list of six other potential buyers who might have the appetite and balance sheet for a deal this size.
None of them stuck around. Three passed almost immediately. A fourth, referred to in filings only as